Device for rapidly detecting podocytosis

Abstract

The invention discloses a device for rapidly detecting podocytosis, and relates to the technical field of biomedical detection. In order to solve the problems that at present, detection of podocytosis mainly depends on kidney biopsy, is traumatic and complex in operation, causes great pain to a patient, and the operation process is complex and needs to be executed by professional medical personnel; however, urine-based podocyte detection avoids biopsy wounds, but generally needs tedious sample treatment steps and professional laboratory equipment, and is not beneficial to rapid screening and diagnosis of diseases. Urine and blood samples are adopted for detection, trauma of kidney biopsy is avoided, the sample treatment and detection process is simplified, the detection time is shortened, the detection efficiency is improved, multiple markers are detected at the same time, the detection accuracy and sensitivity are improved, and by means of marker verification and concentration analysis, the detection accuracy and sensitivity are improved. And a detection report is generated, so that the detection result is more intuitive, and rapid screening and diagnosis of diseases are facilitated.

Description

Technical Field

[0001] The present invention relates to the technical field of biomedical detection, and in particular to a device for quickly detecting podocyte disease. Background Art

[0002] Podocyte disease is a kidney disease, and early diagnosis is of great significance for treatment and prognosis. For example, the patent application with publication number: CN112834532A discloses the use of a urinary podocyte-derived migrator in predicting early glomerular podocyte damage. The migration can be used to predict early glomerular podocyte damage, prompting patients to perform other index tests in a timely manner, which will become an effective means of predicting early glomerular podocyte damage. And the Chinese patent with publication number: CN110490840A discloses a cell detection method, device and equipment for glomerular pathological slice images, wherein the method includes: obtaining a glomerular pathological slice image to be detected; inputting the glomerular pathological slice image to be detected into a preset neural network model for identification and detection, wherein the preset neural network model is obtained by training the neural network with a predetermined number of glomerular pathological slice images for identification and annotation of mesangial cells, endothelial cells and podocytes; outputting the probability map of mesangial cells, endothelial cells and podocytes in the glomerular pathological slice image to be detected from the three output channels of the preset neural network model respectively; calculating the number of mesangial cells, endothelial cells and podocytes in the glomerular pathological slice image to be detected according to the probability map of mesangial cells, endothelial cells and podocytes. Determine the cause and condition of the patient according to the number of mesangial cells, endothelial cells and podocytes, and accurately formulate a treatment plan.

[0003] At present, the detection of podocytosis mainly relies on renal biopsy, which is traumatic and complicated to operate, causing great pain to patients. The operation process is complicated and requires professional medical personnel to perform. Although urine-based podocyte detection avoids the trauma of biopsy, it usually requires cumbersome sample processing steps and professional laboratory equipment, which is not only time-consuming but also complicated to operate, which is not conducive to the rapid screening and diagnosis of the disease. Summary of the invention

[0004] The purpose of the present invention is to provide a device for quickly detecting podocyte disease, which uses urine and blood specimens for detection, avoids the trauma of kidney biopsy, simplifies sample processing and detection procedures, shortens detection time, improves detection efficiency, realizes simultaneous detection of multiple markers, improves detection accuracy and sensitivity, and generates a test report through marker verification and concentration analysis, making the test results more intuitive, which is conducive to the rapid screening and diagnosis of diseases, so as to solve the problems raised in the above-mentioned background technology.

[0005] To achieve the above object, the present invention provides the following technical solutions:

[0006] A device for quickly detecting podocytosis, comprising:

[0007] The sample collection and processing unit is used to obtain urine and blood samples actively submitted by patients for testing, and perform pretreatment to obtain pretreated target urine samples and target blood samples;

[0008] A marker detection unit, used to perform quantitative detection on the pretreated target urine sample and target blood sample, establish a marker standard curve, and obtain the marker concentration in the target urine sample and target blood sample based on the marker standard curve;

[0009] An analysis report generating unit is used for performing podocytosis analysis based on marker concentrations in a target urine sample and a target blood sample and generating a diagnosis report for the patient.

[0010] Furthermore, the sample collection and processing unit comprises:

[0011] The sample acquisition module is used to obtain urine and blood samples from patients and generate unique sample identification codes, match the unique sample identification codes with the patient's urine and blood samples one by one, and monitor the sample collection process, including checking whether the sampling container is sterile and whether the sampling operation complies with the standard process, etc., to ensure that the sample collection process complies with clinical specifications and avoids contamination;

[0012] The sample preprocessing module is used to identify and classify the acquired samples, obtain the patient's urine sample and blood sample, read the sample identification code, and process the urine sample and blood sample separately.

[0013] Furthermore, the sample preprocessing module processes the urine sample and the blood sample separately, specifically:

[0014] The urine sample is placed in a centrifuge tube, and a centrifugal operation is performed according to the centrifugal parameters of the preset speed and centrifugal time to remove cells and particulate impurities in the urine;

[0015] Removing the sediment of the urine sample after centrifugation, retaining the supernatant, and extracting the podocyte marker in the supernatant using a suitable protein extraction method or kit;

[0016] Purifying and concentrating the extracted podocyte markers to remove non-target proteins and other impurities, and increasing the protein concentration by concentration to obtain a target urine sample;

[0017] The blood sample is placed in a centrifuge tube and centrifuged. The speed and time are set according to preset parameters, usually 1500-2000g, centrifuged for 10-15 minutes, to separate the plasma;

[0018] The upper plasma after centrifugation is taken out, and a protein extraction reagent is added to the upper plasma, and the mixture is mixed thoroughly to dissolve the protein in the plasma;

[0019] The mixed mixture is centrifuged again, usually at 12000-16000 g for 10-20 minutes to precipitate the protein, the supernatant is removed, and the precipitated protein is extracted;

[0020] The extracted protein is purified and concentrated to remove non-target proteins and other impurities, and the protein concentration is increased through a concentration step to obtain a target blood sample.

[0021] Furthermore, the process of setting the rotation speed for centrifugal separation of the urine sample includes:

[0022] Extract sample volume and sample density;

[0023] Obtaining an adjustment coefficient according to the sample volume and the sample density;

[0024] The adjustment coefficient is obtained by the following formula:

[0025]

[0026] Wherein, K represents the adjustment coefficient; V represents the sample volume; S represents the sample density; D represents the diameter of the centrifuge tube; r represents the centrifugal radius of the centrifuge;

[0027] Extract centrifuge constants and centrifuge tube diameters;

[0028] The rotation speed is obtained by combining the adjustment coefficient with the centrifuge constant and the diameter of the centrifuge tube, wherein the rotation speed is obtained by the following formula:

[0029]

[0030] Among them, R represents the rotation speed; K represents the adjustment coefficient; V represents the sample volume; S represents the sample density; D represents the diameter of the centrifuge tube; r represents the centrifugal radius of the centrifuge; g represents the gravitational acceleration; w represents the centrifugal angular velocity; and R0 represents the preset initial rotation speed.

[0031] Furthermore, the process of setting the centrifugation time for centrifugal separation of the urine sample includes:

[0032] Extract sample volume and sample density;

[0033] Extract adjustment coefficient and speed;

[0034] The centrifugation time is set using the sample volume and sample density in combination with the adjustment factor and the rotation speed;

[0035] Wherein, the centrifugation time is obtained by the following formula:

[0036]

[0037] Wherein, T represents the centrifugation time; T0 represents the preset initial centrifugation time; R represents the rotation speed; K represents the adjustment coefficient; V represents the sample volume; and S represents the sample density.

[0038] Furthermore, the marker detection unit comprises:

[0039] Urine detection module, used for quantitative detection of podocyte injury markers in target urine samples, such as B7-1, nephrin, podocin, podocalyxin, WT I, etc.;

[0040] A blood testing module, used for quantitatively detecting podocyte injury markers in a target blood sample;

[0041] The marker verification module is used to compare the quantitative test results of the target urine sample and the target blood sample based on the established marker standard curve, determine the marker concentrations of the target urine sample and the target blood sample, and verify the accuracy of the test results.

[0042] Furthermore, the urine detection module performs quantitative detection, specifically including:

[0043] Adding the target urine sample to a detection device containing a podocyte injury marker antibody, wherein the target urine sample reacts with the antibody in the detection device to form an antigen-antibody complex;

[0044] After cleaning the detection device, adding a marker capable of reacting with the antigen-antibody complex to the detection device;

[0045] After the detection device is cleaned again, a substrate solution is added to the detection device, a color change is produced based on the reaction of the marker with the antigen-antibody complex, the substrate is allowed to react for a certain time to develop the color, and the absorbance value of the detection device is measured, which is proportional to the concentration of the podocyte injury marker in the urine sample;

[0046] The blood detection module and the urine detection module use the same steps and processes to perform quantitative detection.

[0047] Furthermore, the marker verification module is specifically:

[0048] A curve establishment submodule, for processing and testing the marker standards according to the same steps as the urine and blood testing modules based on no less than five marker standards of known concentration, obtaining the absorbance value of the marker standard corresponding to each concentration, and establishing a marker standard curve based on the absorbance value;

[0049] The quality verification submodule is used to establish a urine sample marker curve and a blood sample marker curve based on the absorbance values ​​of the target urine sample and the target blood sample, and compare them with the marker standard curve to determine whether the test results of the target urine sample and the target blood sample are abnormal. If the sample results deviate from the standard curve, perform quality control checks, including repeating the test, checking the reagent batch, and the calibration status of the equipment, etc.;

[0050] A quantification submodule, for converting the absorbance values ​​of the target urine sample and the target blood sample into marker concentrations based on the marker standard curve to obtain the marker concentrations of the target urine sample and the target blood sample, and at the same time, performing multiple measurements on each target sample and calculating an average value to improve accuracy;

[0051] The cross-validation submodule is used to ensure the consistency of the results of the urine and blood test modules, obtain and compare the test results of the urine and blood samples of the same patient, compare the concentrations of the same markers in the two sample types, and analyze the reasons for the differences, such as differences in sample processing, differences in urine and blood concentrations of biomarkers, etc.

[0052] Furthermore, the analysis report generating unit includes:

[0053] A test result analysis module, used to obtain the absorbance value and marker concentration data output by the marker detection unit, generate the test result of each sample, compare the marker concentration of the target urine sample and the target blood sample with the pre-set normal value range, identify the samples that are beyond the normal range based on the test results, and mark them as potential abnormal samples;

[0054] The diagnostic report generation module is used to mark the abnormal types of samples marked as potentially abnormal, taking into account possible factors such as sample contamination, reagent batch differences, individual differences among patients, etc., and to generate a diagnostic report containing diagnostic suggestions and follow-up examination suggestions, including marker concentrations, normal value range comparison results, statistical analysis results, trend analysis, etc.

[0055] Furthermore, the detection result analysis module also includes:

[0056] Based on the existence of potentially abnormal samples, obtain the patient data corresponding to the samples and obtain the patient's historical test data, including the concentration of podocyte injury markers, test date, test time, test method, test results, etc.;

[0057] Extract marker concentrations from historical test data based on time series, perform trend analysis, identify changing trends in marker concentrations, and compare the rates of change between different markers to identify possible correlations;

[0058] Based on the changing trend of marker concentrations and the change rate between different markers, the progression of the disease and the treatment effect are evaluated.

[0059] Compared with the prior art, the present invention has the following beneficial effects:

[0060] The sample collection and processing unit ensures the purity of the samples and standardized processing before testing, reduces experimental errors, and improves the reliability of testing. The quantitative detection and standard curve establishment of the marker detection unit provide a scientific basis for the accurate determination of concentration, making the test results highly consistent and repeatable. The comprehensive data analysis of the analysis report generation unit not only provides doctors with detailed diagnostic information, but also reveals the development of the disease through trend analysis and historical data comparison, which helps to formulate more accurate treatment plans and facilitates the early screening and monitoring of podocytosis, thereby improving the quality of life of patients while reducing medical costs and social burdens. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 This is a module diagram of the device for quickly detecting podocyte disease of the present invention. DETAILED DESCRIPTION

[0062] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0063] In order to solve the current problem that the detection of podocyte disease mainly relies on kidney biopsy, which is invasive and complicated to operate, causing great pain to patients, and the operation process is complicated and requires professional medical personnel to perform; while urine-based podocyte detection avoids the trauma of biopsy, it usually requires cumbersome sample processing steps and professional laboratory equipment, which is not conducive to the rapid screening and diagnosis of the disease. Figure 1 , this embodiment provides the following technical solutions:

[0064] A device for quickly detecting podocytosis, comprising:

[0065] The sample collection and processing unit is used to obtain urine and blood samples actively submitted by patients for testing, and perform pretreatment to obtain pretreated target urine samples and target blood samples;

[0066] A marker detection unit, used to perform quantitative detection on the pretreated target urine sample and target blood sample, establish a marker standard curve, and obtain the marker concentration in the target urine sample and target blood sample based on the marker standard curve;

[0067] An analysis report generating unit is used for performing podocytosis analysis based on marker concentrations in a target urine sample and a target blood sample and generating a diagnosis report for the patient.

[0068] In this embodiment, the sample collection and processing unit includes:

[0069] The sample acquisition module is used to obtain urine and blood samples from patients and generate unique sample identification codes, match the unique sample identification codes with the patient's urine and blood samples one by one, and monitor the sample collection process, including checking whether the sampling container is sterile and whether the sampling operation complies with the standard process, etc., to ensure that the sample collection process complies with clinical specifications and avoids contamination;

[0070] The sample preprocessing module is used to identify and classify the acquired samples, obtain the patient's urine sample and blood sample, read the sample identification code, and process the urine sample and blood sample separately. Specifically:

[0071] The urine sample is placed in a centrifuge tube, and a centrifugal operation is performed according to the centrifugal parameters of the preset speed and centrifugal time to remove cells and particulate impurities in the urine;

[0072] Removing the sediment of the urine sample after centrifugation, retaining the supernatant, and extracting the podocyte marker in the supernatant using a suitable protein extraction method or kit;

[0073] Purifying and concentrating the extracted podocyte markers to remove non-target proteins and other impurities, and increasing the protein concentration by concentration to obtain a target urine sample;

[0074] The blood sample is placed in a centrifuge tube and centrifuged. The speed and time are set according to preset parameters, usually 1500-2000g, centrifuged for 10-15 minutes, to separate the plasma;

[0075] The upper plasma after centrifugation is taken out, and a protein extraction reagent (such as a protein extraction buffer) is added to the upper plasma, and the mixture is mixed thoroughly to dissolve the protein in the plasma;

[0076] The mixed mixture is centrifuged again, usually at 12000-16000 g for 10-20 minutes to precipitate the protein, the supernatant is removed, and the precipitated protein is extracted;

[0077] The extracted protein is purified and concentrated to remove non-target proteins and other impurities, and the protein concentration is increased through a concentration step to obtain a target blood sample.

[0078] In this embodiment, sample tracking is achieved through the generation and application of a unique sample identification code, ensuring the rigor of the detection process, pre-treating the sample to effectively remove impurities, and increasing the protein concentration, providing high-purity samples for subsequent marker detection, improving detection sensitivity and specificity, and reducing experimental errors, providing a reliable basis for the accurate diagnosis and treatment of podocyte injury, thereby helping to improve the treatment effect and quality of life of patients.

[0079] Specifically, the process of setting the rotation speed for centrifugal separation of the urine sample includes:

[0080] Extract sample volume and sample density;

[0081] Obtaining an adjustment coefficient according to the sample volume and the sample density;

[0082] The adjustment coefficient is obtained by the following formula:

[0083]

[0084] Wherein, K represents the adjustment coefficient; V represents the sample volume; S represents the sample density; D represents the diameter of the centrifuge tube; r represents the centrifugal radius of the centrifuge;

[0085] Extract centrifuge constants and centrifuge tube diameters;

[0086] The rotation speed is obtained by combining the adjustment coefficient with the centrifuge constant and the diameter of the centrifuge tube, wherein the rotation speed is obtained by the following formula:

[0087]

[0088] Among them, R represents the rotation speed; K represents the adjustment coefficient; V represents the sample volume; S represents the sample density; D represents the diameter of the centrifuge tube; r represents the centrifugal radius of the centrifuge; g represents the gravitational acceleration; w represents the centrifugal angular velocity; and R0 represents the preset initial rotation speed.

[0089] The technical effect of the above technical solution is: by extracting the volume (V) and density (S) of the sample, and combining the diameter (D) of the centrifuge tube and the centrifugal radius (r) of the centrifuge, the adjustment coefficient (K) is calculated. This adjustment coefficient takes into account the physical properties of the sample and the parameters of the centrifugal equipment, so that the subsequent speed setting is more in line with the actual needs of the sample. Using the adjustment coefficient (K), centrifuge constant, diameter of the centrifuge tube (D), sample volume (V), sample density (S), centrifugal radius of the centrifuge (r), gravitational acceleration (g) and centrifugal angular velocity (w) and other parameters, the speed (R) is calculated by formula. This calculation method takes into account multiple factors and helps to improve the accuracy of centrifugal separation.

[0090] By accurately calculating the rotation speed, it can be ensured that the centrifugal separation process is carried out under optimal conditions, thereby shortening the separation time and improving the separation efficiency. The preset initial rotation speed (R0) may be an optimized value based on experience or experimental data. Combined with fine-tuning of the adjustment coefficient, the high efficiency of centrifugal separation can be further ensured. This technical solution adapts to urine samples of different volumes and densities by calculating the adjustment coefficient, making the centrifugal separation process more flexible and universal. By adjusting the rotation speed, it can adapt to changes in different centrifuge tube diameters and centrifugal radii of the centrifuge, thereby enhancing the applicability of centrifugal separation. Through standardized calculation processes and parameter settings, it can be ensured that the conditions of each centrifugal separation experiment are as consistent as possible, thereby improving the repeatability and consistency of the experiment. This is crucial for scientific research, clinical diagnosis and other fields, and can ensure the accuracy and reliability of experimental results.

[0091] In summary, this technical solution improves the accuracy, efficiency, applicability, repeatability and consistency of centrifugal separation by accurately calculating the rotation speed and comprehensively considering the physical properties of the sample and the parameters of the centrifugal equipment. This has important technical significance and application value for the centrifugal separation of urine samples.

[0092] Specifically, the process of setting the centrifugal time for centrifugal separation of the urine sample includes:

[0093] Extract sample volume and sample density;

[0094] Extract adjustment coefficient and speed;

[0095] The centrifugation time is set using the sample volume and sample density in combination with the adjustment factor and the rotation speed;

[0096] Wherein, the centrifugation time is obtained by the following formula:

[0097]

[0098] Wherein, T represents the centrifugation time; T0 represents the preset initial centrifugation time; R represents the rotation speed; K represents the adjustment coefficient; V represents the sample volume; and S represents the sample density.

[0099] The technical effect of the above technical solution is: by extracting the volume (V) and density (S) of the sample, and combining the adjustment coefficient (K) and speed (R) calculated previously, the centrifugation time (T) can be customized. This setting method takes into account the specific physical properties of the sample and the operating parameters of the centrifugal device, so that the centrifugation process is more in line with the actual needs of the sample. By using the formula to calculate the centrifugation time, it can be ensured that the sample achieves the expected separation effect at the appropriate speed and adjustment coefficient. This helps to reduce unnecessary centrifugation time and improve separation efficiency. At the same time, by setting the centrifugation time accurately, it can be ensured that the different components in the sample are fully separated and the separation effect is improved. Through standardized calculation processes and parameter settings, it can be ensured that the conditions of each centrifugation experiment are as consistent as possible, thereby enhancing the controllability of centrifugation. In addition, since the centrifugation time is calculated by a formula, the centrifugation effect of different samples under different conditions can be predicted, which facilitates experimental design and data analysis. By ensuring that the conditions of each centrifugation experiment are consistent, the repeatability of the experiment can be improved. This is crucial for research that requires repeated experiments to verify the results. At the same time, consistent experimental conditions also help to improve the consistency of experimental results, so that experimental results between different batches or different laboratories can be compared and verified with each other. The centrifugal separation operation process can be simplified by calculating the centrifugal time through the formula. The experimenter only needs to input the basic information such as the volume and density of the sample, as well as the parameters of the centrifugal equipment (such as speed, adjustment coefficient, etc.), and the centrifugal time can be automatically calculated without the tedious trial and error and adjustment process.

[0100] In summary, this technical solution improves the customization, efficiency and effect, controllability and predictability, repeatability and consistency of centrifugal separation by accurately calculating the centrifugation time and comprehensively considering the physical properties of the sample and the parameters of the centrifugal equipment, and simplifies the operation process of centrifugal separation. This has important technical significance and application value for the centrifugal separation of urine samples.

[0101] In this embodiment, the marker detection unit includes:

[0102] Urine detection module, used for quantitative detection of podocyte injury markers in target urine samples, such as B7-1, nephrin, podocin, podocalyxin, WTI, etc.;

[0103] A blood testing module, used for quantitatively detecting podocyte injury markers in a target blood sample;

[0104] In this embodiment, the urine detection module performs quantitative detection, specifically including:

[0105] Adding the target urine sample to a detection device containing a podocyte injury marker antibody, wherein the target urine sample reacts with the antibody in the detection device to form an antigen-antibody complex;

[0106] After cleaning the detection device, adding a marker capable of reacting with the antigen-antibody complex to the detection device;

[0107] After the detection device is cleaned again, a substrate solution is added to the detection device, a color change is produced based on the reaction of the marker with the antigen-antibody complex, the substrate is allowed to react for a certain time to develop the color, and the absorbance value of the detection device is measured, which is proportional to the concentration of the podocyte injury marker in the urine sample;

[0108] The blood testing module and the urine testing module use the same steps and processes to perform quantitative testing;

[0109] In this embodiment, by performing quantitative detection on the target sample, the accurate determination of the concentration of the podocyte injury marker in the urine sample and the blood sample is ensured, and a standardized and repeatable detection process is provided, so that the detection results are highly consistent between different laboratories and different time points, and the quantification of the marker concentration is achieved;

[0110] The marker verification module is used to compare the quantitative test results of the target urine sample and the target blood sample based on the established marker standard curve, determine the marker concentrations of the target urine sample and the target blood sample, and verify the accuracy of the test results.

[0111] In this embodiment, quantitative detection is used to ensure accurate determination of the concentration of podocyte injury markers in urine and blood samples, providing reliable laboratory data for the diagnosis of podocytosis. A standardized detection process is used to ensure that the test results are highly consistent between different laboratories and at different time points, which is convenient for clinical application and large-scale promotion. By comparing the quantitative test results of urine samples and blood samples and using the established marker standard curve, the accuracy of the test results is ensured. Early detection of podocyte injury markers helps to intervene in the early stages of disease development, thereby improving the prognosis of patients.

[0112] In this embodiment, the marker verification module is specifically:

[0113] A curve establishment submodule, for processing and testing the marker standards according to the same steps as the urine and blood testing modules based on no less than five marker standards of known concentration, obtaining the absorbance value of the marker standard corresponding to each concentration, and establishing a marker standard curve based on the absorbance value;

[0114] The quality verification submodule is used to establish a urine sample marker curve and a blood sample marker curve based on the absorbance values ​​of the target urine sample and the target blood sample, and compare them with the marker standard curve to determine whether the test results of the target urine sample and the target blood sample are abnormal. If the sample results deviate from the standard curve, perform quality control checks, including repeating the test, checking the reagent batch, and the calibration status of the equipment, etc.;

[0115] A quantification submodule, for converting the absorbance values ​​of the target urine sample and the target blood sample into marker concentrations based on the marker standard curve to obtain the marker concentrations of the target urine sample and the target blood sample, and at the same time, performing multiple measurements on each target sample and calculating an average value to improve accuracy;

[0116] The cross-validation submodule is used to ensure the consistency of the results of the urine and blood test modules, obtain and compare the test results of the urine and blood samples of the same patient, compare the concentrations of the same markers in the two sample types, and analyze the reasons for the differences, such as differences in sample processing, differences in urine and blood concentrations of biomarkers, etc.

[0117] In this embodiment, by establishing a standard curve, an accurate basis for concentration conversion is provided for subsequent sample testing, the accuracy of sample testing is monitored in real time, potential errors are discovered and corrected in a timely manner, and the accuracy of concentration determination is improved by multiple measurements and calculation of average values; by comparing the test results of urine and blood samples of the same patient, the consistency of testing of different sample types is ensured, thereby providing comprehensive and reliable biomarker data for clinical diagnosis, significantly improving the stability and repeatability of the detection process, and helping to improve patient prognosis and reduce misdiagnosis rates.

[0118] In this embodiment, the analysis report generating unit includes:

[0119] The test result analysis module is used to obtain the absorbance value and marker concentration data output by the marker detection unit, generate the test results of each sample, compare the marker concentration of the target urine sample and the target blood sample with the pre-set normal value range, identify the samples that are out of the normal range based on the test results, and mark them as potential abnormal samples, and also includes:

[0120] Based on the existence of potentially abnormal samples, obtain the patient data corresponding to the samples and obtain the patient's historical test data, including the concentration of podocyte injury markers, test date, test time, test method, test results, etc.;

[0121] Extract marker concentrations from historical test data based on time series, perform trend analysis, identify changing trends in marker concentrations, and compare the rates of change between different markers to identify possible correlations;

[0122] Evaluate the progression of the disease and the effectiveness of treatment based on the changing trends of marker concentrations and the rates of change between different markers;

[0123] The diagnostic report generation module is used to mark the abnormal types of samples marked as potentially abnormal, taking into account possible factors such as sample contamination, reagent batch differences, individual differences among patients, etc., and to generate a diagnostic report containing diagnostic recommendations (such as whether further examinations or treatments, medical evaluations and interventions are needed) and follow-up examination recommendations (such as the timing and type of follow-up examinations), including marker concentrations, normal value range comparison results, statistical analysis results, trend analysis, etc.

[0124] In this embodiment, the analysis report generation unit accurately analyzes the concentration of podocyte injury markers in urine and blood samples, not only the absorbance values ​​and marker concentration data of the samples are obtained and compared, but also the patient's historical test data is integrated and trend analysis is performed to identify the changing trend of marker concentrations and the correlation between different markers, and provides detailed diagnostic suggestions and follow-up examination suggestions for samples with potential abnormalities, which not only improves the accuracy of diagnosis, but also promotes early detection and intervention, optimizes treatment plans, and improves the efficiency of patient management through personalized medical advice and systematic reporting, and promotes effective communication between doctors and patients.

[0125] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. A device for quickly detecting podocyte disease, characterized in that: include: The sample collection and processing unit is used to obtain urine and blood samples actively submitted by patients for testing, and perform pretreatment to obtain pretreated target urine samples and target blood samples; A marker detection unit, used to perform quantitative detection on the pretreated target urine sample and target blood sample, establish a marker standard curve, and obtain the marker concentration in the target urine sample and target blood sample based on the marker standard curve; An analysis report generating unit is used for performing podocytosis analysis based on marker concentrations in a target urine sample and a target blood sample and generating a diagnosis report for the patient.

2. A device for rapid detection of podocyte disease as claimed in claim 1, characterized in that: Sample collection and processing unit, including: A sample acquisition module is used to obtain urine and blood samples from patients, generate unique sample identification codes, match the unique sample identification codes with the urine and blood samples of patients one by one, and monitor the sample collection process; The sample preprocessing module is used to identify and classify the acquired samples, obtain the patient's urine sample and blood sample, read the sample identification code, and process the urine sample and blood sample separately.

3. A device for rapid detection of podocyte disease as claimed in claim 2, characterized in that: The sample preprocessing module processes urine samples and blood samples separately, specifically: The urine sample is placed in a centrifuge tube, and a centrifuge operation is performed according to the centrifuge parameters of the preset speed and centrifuge time; removing the precipitate of the urine sample after centrifugation, retaining the supernatant, and performing an extraction operation on the podocyte marker in the supernatant; Purifying and concentrating the extracted podocyte markers to obtain a target urine sample; The blood sample is placed in a centrifuge tube and centrifuged. The speed and time of the centrifuge are set according to preset parameters to separate the plasma. The upper plasma after centrifugation is taken out, and a protein extraction reagent is added to the upper plasma and mixed thoroughly; The mixed mixture was centrifuged again, the supernatant was removed, and the precipitated protein was extracted; The extracted protein is purified and concentrated to obtain a target blood sample.

4. A device for rapid detection of podocyte disease as claimed in claim 3, characterized in that: The process of setting the rotation speed for centrifugal separation of the urine sample includes: Extract sample volume and sample density; Obtaining an adjustment coefficient according to the sample volume and the sample density; The adjustment coefficient is obtained by the following formula: Wherein, K represents the adjustment coefficient; V represents the sample volume; S represents the sample density; D represents the diameter of the centrifuge tube; r represents the centrifugal radius of the centrifuge; Extract centrifuge constants and centrifuge tube diameters; The rotation speed is obtained by combining the adjustment coefficient with the centrifuge constant and the diameter of the centrifuge tube, wherein the rotation speed is obtained by the following formula: Among them, R represents the rotation speed; K represents the adjustment coefficient; V represents the sample volume; S represents the sample density; D represents the diameter of the centrifuge tube; r represents the centrifugal radius of the centrifuge; g represents the gravitational acceleration; w represents the centrifugal angular velocity; R0 represents the preset initial rotation speed.

5. A device for rapid detection of podocyte disease as claimed in claim 3, characterized in that: The process of setting the centrifugation time for centrifugal separation of the urine sample includes: Extract sample volume and sample density; Extract adjustment coefficient and speed; The centrifugation time is set using the sample volume and sample density in combination with the adjustment factor and the rotation speed; Wherein, the centrifugation time is obtained by the following formula: Wherein, T represents the centrifugation time; T0 represents the preset initial centrifugation time; R represents the rotation speed; K represents the adjustment coefficient; V represents the sample volume; and S represents the sample density.

6. A device for rapid detection of podocyte disease as claimed in claim 3, characterized in that: A marker detection unit, comprising: A urine testing module, used for quantitatively detecting podocyte injury markers in a target urine sample; A blood testing module, used for quantitatively detecting podocyte injury markers in a target blood sample; The marker verification module is used to compare the quantitative detection results of the target urine sample and the target blood sample based on the established marker standard curve to determine the marker concentrations of the target urine sample and the target blood sample.

7. A device for rapid detection of podocyte disease as claimed in claim 6, characterized in that: The urine detection module performs quantitative detection, specifically including: Adding the target urine sample to a detection device containing a podocyte injury marker antibody, wherein the target urine sample reacts with the antibody in the detection device to form an antigen-antibody complex; After cleaning the detection device, adding a marker capable of reacting with the antigen-antibody complex to the detection device; After the detection device is cleaned again, a substrate solution is added to the detection device, a color change is produced based on the reaction of the marker and the antigen-antibody complex, and the absorbance value of the detection device is measured.

8. A device for rapid detection of podocyte disease as claimed in claim 7, characterized in that: Marker verification module, specifically: A curve establishment submodule, for obtaining the absorbance value of the marker standard corresponding to each concentration based on no less than five marker standards of known concentrations, and establishing a marker standard curve based on the absorbance value; A quality verification submodule, for establishing a urine sample marker curve and a blood sample marker curve based on the absorbance values ​​of the target urine sample and the target blood sample, and comparing them with the marker standard curve to determine whether the test results of the target urine sample and the target blood sample are abnormal; A quantification submodule, used for converting the absorbance values ​​of the target urine sample and the target blood sample into marker concentrations based on the marker standard curve to obtain the marker concentrations of the target urine sample and the target blood sample; The cross-validation submodule is used to obtain and compare the test results of urine and blood samples from the same patient, compare the concentrations of the same markers in the two sample types, and analyze the reasons for the differences.

9. A device for rapid detection of podocyte disease as claimed in claim 8, characterized in that: Analysis report generation unit, including: A test result analysis module is used to obtain the absorbance value and marker concentration data output by the marker detection unit, generate the test result of each sample, identify samples that are out of the normal range based on the test results, and mark them as potential abnormal samples; The diagnostic report generation module is used to mark the abnormality type of samples marked as potentially abnormal and generate a diagnostic report containing diagnostic suggestions and follow-up examination suggestions.

10. A device for rapid detection of podocyte disease according to claim 9, characterized in that: The test result analysis module also includes: Based on the existence of potentially abnormal samples, obtain patient data corresponding to the samples and obtain historical test data of the patients; Extract marker concentrations from historical test data based on time series, perform trend analysis, identify changing trends in marker concentrations, and compare the rates of change between different markers; Based on the changing trend of marker concentrations and the change rate between different markers, the progression of the disease and the treatment effect are evaluated.

Images